Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
WT1-loaded CBDC vaccine
- Development stage
- Unknown
- Lead developer
- Princess Máxima Center for Pediatric Oncology
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
WT1-loaded CBDC vaccine is an autologous cellular immunotherapy consisting of dendritic cells derived from cord blood (CBDC) and loaded with Wilms' Tumor 1 (WT1) peptides. Developed by the Princess Máxima Center for Pediatric Oncology, this vaccine is designed for pediatric and young adult patients with acute myeloid leukemia (AML) who have undergone cord blood allogeneic hematopoietic cell transplantation (HCT). The vaccine aims to stimulate a WT1-specific T-cell response to target and eliminate residual leukemic cells that overexpress the WT1 protein, thereby reducing the risk of post-transplant relapse. This approach is unique in its use of cord blood as the source for dendritic cell generation, specifically tailored for patients receiving cord blood transplants.
- Other names
- WT1-loaded cord blood-derived dendritic cell vaccineWT-1-loaded cord blood-derived dendritic cell vaccineWT 1-loaded cord blood-derived dendritic cell vaccineCBDC-WT1 vaccineCBDC-WT-1 vaccineCBDC-WT 1 vaccineWT1-loaded CBDC VaccineWT-1-loaded CBDC VaccineWT 1-loaded CBDC Vaccine
Beyond the preview
Go deeper on WT1-loaded CBDC vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on WT1-loaded CBDC vaccine.